secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-058017
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q1 2024 revenue $29.5M, net loss $8.2M; acquires GAVRETO, appoints CMO
----------------------------------------------------------------------------

- TAVALISSE net sales $21.1M (down from $22.3M) but bottles shipped hit highest quarterly level since launch.
- REZLIDHIA net sales $4.9M, up from $1.5M YoY, driven by increased demand.
- Net loss improved to $8.2M ($0.05/sh) from $13.5M ($0.08/sh) in Q1 2023.
- Acquired U.S. rights to GAVRETO (pralsetinib) for RET fusion-positive NSCLC/thyroid cancer; transition expected July 2024.
- Cash and short-term investments $49.6M at March 31, 2024; credit facility amendment extended maturity by one year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/0001104659-24-058017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924058017/tm2413689d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer